Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2016

View Archived Issues

FDA grants tazemetostat orphan drug designation for the treatment of rhabdoid tumors

ONL-1204 granted orphan drug designation in U.S. for retinal detachment

RedHill Biopharma gives update on Bekinda studies

Otsuka Pharmaceutical reports pipeline developments of fourth quarter 2015

Renova Therapeutics and Lonza enter manufacturing agreement for RT-100

FDA names epacadostat an orphan drug for stage IIB-IV melanoma

Placental-derived stem cells for the treatment for erectile dysfunction

MGB Biopharma and UoS sign an agreement to develop novel anti-infective agents

OPKO Health acquires interest in Xenetic Biosciences

Promising results reported in nanotechonolgy applied to molecurlay targeted cancer therapy

Sunshine Lake Pharma patents CDK4 and/or CDK6 inhibitors

ValiRx advances clinical trial of VAL-201

Roche divulges TaR-1 ligands

Gilead Sciences discloses antiviral agents

Siena Biotech and Roche report BACE1 inhibitors

Phase III study of Aranesp in MDS meets primary endpoint

Scientists from Scripps Research Institute win grant to advance Huntington's disease research

FDA issues complete response letter for Zetia and Vytorin

Pharnext advances pleotherapy-based treatments for rare diseases

Sanofi K.K. announces merger with Genzyme Japan

Shionogi joins Cambridge Therapeutics Consortium

European approval for Portrazza for advanced squamous NSCLC

CXCR4 antagonist obtains FDA orphan drug designation for glioblastoma multiforme

Intramuscular administration of obiltoxaximab well tolerated in healthy adults

GtreeBNT acquires rights to glioblastoma treatment OKN-007 from OMRF

Newly developed EGF-targeting peptides block EGF-EGFR interaction

AstraZeneca establishes new collaborations in CKD